Description
The combination of empagliflozin, metformin, and linagliptin is used to treat type 2 diabetes by lowering high blood sugar levels, primarily through a combination of mechanisms that include increasing insulin release, reducing sugar absorption from the intestines, and decreasing the liver’s production of sugar; it is typically prescribed alongside a proper diet and exercise regimen, and can also be used to lower the risk of cardiovascular death in patients with type 2 diabetes and established heart disease.
Additional information
| brand | Highnoon Laboratories |
|---|
